Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
USPs of Gastrointestinal API
- Customized Particle Size Distribution
- Multiple manufacturing units
- High degree of supply assurance
- Vertically Integrated
- Manufacture capacity of 100 multi-tones of prazole APIs
- Supplier to 50 pharma companies across more than 25 countries for Gastrointestinal APIs.
- Well-positioned to meet the global demand for high quality Prazole APIs
- Active DMFs in all key markets
- Proven track record as strong player in Prazole family both as APIs and Finished formulations
- Multiple PSD Specs in place with validated size reduction process
- Nitrosamine impurities assessment reports available
- Meets Pharmacopeia requirements for US, EU, China, and Japan
- Manufacturing and supply chain assurance
- Favorable IP
Gastrointestinal API Products Manufacturer and Supplier
Dr. Reddy's offers a wide selection of Gastrointestinal APIs in the class of molecules that include - Proton pump inhibitors, H2-receptor antagonists, 5-HT3 receptor antagonists, laxatives, etc. We have established leaders in the GI therapeutic area, i.e., Proton pump inhibitors and the market leaders in the Prazole franchise APIs. As a Gastrointestinal API manufacturer and Gastrointestinal API supplier, Dr. Reddy's manufactures large volumes of gastrointestinal APIs consistently to cater to global demand and can offer a customized particle size distribution to meet our customer formulation needs.
- Proton Pump Inhibitors
- Anti-emetics
- Anti-constipation
- H2-receptor antagonists
- PBC
- Non-alcoholic steatohepatitis
PPIs- inhibit the proton (H+-K+–ATPase) pump of the parietal cells in the stomach. Anti-emetics - blocks specific receptors that respond to neurotransmitter molecules, such as serotonin, dopamine & histamine. H2RAs decrease gastric acid secretion by reversibly binding to histamine H2 receptors located on gastric parietal cells.
- The global pandemic COVID-19 has positively affected the global gastrointestinal drug market share.
- Owing to the increasing cases of gastric diseases, huge investments have been made by manufacturers for the development of gastrointestinal treatment.
- The market share for GTI drugs is expected to grow in the coming years.
The global gastrointestinal drugs market is expected to grow from $46.68 billion in 2020 to $48.74 billion in 2021 at a CAGR of 4.4%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during COVID-19.
Used to treat people with heartburn, stomach or intestinal ulcers, or excess stomach acid. Proton pump inhibitors reduce acid by shutting down the tiny pumps within cells in your stomach that secrete it.
Renuncia
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.